This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kamada, T. Articles by Tateishi, A. Search for Related Content PubMed PubMed Citation Articles by Kamada, T. Articles by Tateishi, A. Social Bookmarking                            What's this?

Efficacy and Safety of Carbon Ion Radiotherapy in Bone and Soft Tissue Sarcomas

From the Research Center Hospital for Charged Particle Therapy, National Institute of Radiological Sciences, and Chiba University Graduate School of Medicine, Chiba, Japan.

Address reprint requests to Tadashi Kamada, MD, Research Center Hospital for Charged Particle Therapy, National Institute of Radiological Sciences, Anagawa-4-9-1, Inage-Ku, Chiba 261, Japan; email: t_kamada{at}nirs.go.jp

PURPOSE: To evaluate the tolerance for and effectiveness of carbon ion radiotherapy in patients with unresectable bone and soft tissue sarcomas.

PATIENTS AND METHODS: We conducted a phase I/II dose escalation study of carbon ion radiotherapy. Fifty-seven patients with 64 sites of bone and soft tissue sarcomas not suited for resection received carbon ion radiotherapy. Tumors involved the spine or paraspinous soft tissues in 19 patients, pelvis in 32 patients, and extremities in six patients. The total dose ranged from 52.8 to 73.6 gray equivalent (GyE) and was administered in 16 fixed fractions over 4 weeks (3.3 to 4.6 GyE/fraction). The median tumor size was 559 cm³ (range, 20 to 2,290 cm³). The minimum follow-up was 18 months.

RESULTS: Seven of 17 patients treated with the highest total dose of 73.6 GyE experienced Radiation Therapy Oncology Group grade 3 acute skin reactions. Dose escalation was then halted at this level. No other severe acute reactions (grade > 3) were observed in this series. The overall local control rates were 88% and 73% at 1 year and 3 years of follow-up, respectively. The median survival time was 31 months (range, 2 to 60 months), and the 1- and 3-year overall survival rates were 82% and 46%, respectively.

CONCLUSION: Carbon ion radiotherapy seems to be a safe and effective modality in the management of bone and soft tissue sarcomas not eligible for surgical resection, providing good local control and offering a survival advantage without unacceptable morbidity.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				J.-Y. Blay and A. Le Cesne Adjuvant Chemotherapy in Localized Soft Tissue Sarcomas: Still Not Proven Oncologist, October 1, 2009; 14(10): 1013 - 1020. [Abstract] [Full Text] [PDF]

				K. Nojiri, M. Iwakawa, Y. Ichikawa, K. Imadome, M. Sakai, M. Nakawatari, K.-I. Ishikawa, A. Ishikawa, S. Togo, H. Tsujii, et al. The Proangiogenic Factor Ephrin-A1 Is Up-Regulated in Radioresistant Murine Tumor by Irradiation Experimental Biology and Medicine, January 1, 2009; 234(1): 112 - 122. [Abstract] [Full Text] [PDF]

				M. Hoshi, M. Ieguchi, M. Takami, M. Aono, S. Taguchi, T. Kuroda, and K. Takaoka Clinical Problems After Initial Unplanned Resection of Sarcoma Jpn. J. Clin. Oncol., October 1, 2008; 38(10): 701 - 709. [Abstract] [Full Text] [PDF]

				D. Schulz-Ertner and H. Tsujii Particle Radiation Therapy Using Proton and Heavier Ion Beams J. Clin. Oncol., March 10, 2007; 25(8): 953 - 964. [Abstract] [Full Text] [PDF]

				B. Fuchs, I. D. Dickey, M. J. Yaszemski, C. Y. Inwards, and F. H. Sim Operative Management of Sacral Chordoma J. Bone Joint Surg. Am., October 1, 2005; 87(10): 2211 - 2216. [Abstract] [Full Text] [PDF]

				P. van Luijk, A. Novakova-Jiresova, H. Faber, J. M. Schippers, H. H. Kampinga, H. Meertens, and R. P. Coppes Radiation Damage to the Heart Enhances Early Radiation-Induced Lung Function Loss Cancer Res., August 1, 2005; 65(15): 6509 - 6511. [Abstract] [Full Text] [PDF]

				B. Jones and N. Burnet Radiotherapy for the future BMJ, April 30, 2005; 330(7498): 979 - 980. [Full Text] [PDF]

				B Jones and I Rosenberg Particle Therapy Co-operative Oncology Group (PTCOG 40) Meeting, Institute Curie 2004 Br. J. Radiol., February 1, 2005; 78(926): 99 - 102. [Full Text] [PDF]

				T. Ogata, T. Teshima, K. Kagawa, Y. Hishikawa, Y. Takahashi, A. Kawaguchi, Y. Suzumoto, K. Nojima, Y. Furusawa, and N. Matsuura Particle Irradiation Suppresses Metastatic Potential of Cancer Cells Cancer Res., January 1, 2005; 65(1): 113 - 120. [Abstract] [Full Text] [PDF]

				R. Imai, T. Kamada, H. Tsuji, T. Yanagi, M. Baba, T. Miyamoto, S. Kato, S. Kandatsu, J.-e. Mizoe, H. Tsujii, et al. Carbon Ion Radiotherapy for Unresectable Sacral Chordomas Clin. Cancer Res., September 1, 2004; 10(17): 5741 - 5746. [Abstract] [Full Text] [PDF]

				H. Zhang, K. Yoshikawa, K. Tamura, T. Tomemori, K. Sagou, M. Tian, S. Kandatsu, T. Kamada, H. Tsuji, T. Suhara, et al. [11C]Methionine Positron Emission Tomography and Survival in Patients with Bone and Soft Tissue Sarcomas Treated by Carbon Ion Radiotherapy Clin. Cancer Res., March 1, 2004; 10(5): 1764 - 1772. [Abstract] [Full Text] [PDF]

				R. Gorlick, P. Anderson, I. Andrulis, C. Arndt, G. P. Beardsley, M. Bernstein, J. Bridge, N.-K. Cheung, J. S. Dome, D. Ebb, et al. Biology of Childhood Osteogenic Sarcoma and Potential Targets for Therapeutic Development: Meeting Summary Clin. Cancer Res., November 15, 2003; 9(15): 5442 - 5453. [Abstract] [Full Text] [PDF]

				P. M. Anderson Effectiveness of Radiotherapy for Osteosarcoma That Responds to Chemotherapy Mayo Clin. Proc., February 1, 2003; 78(2): 145 - 146. [PDF]